Completed PHASE3 INTERVENTIONAL 2-arm NCT01651780

Open-label, Randomized Trial in Participants Undergoing TAVR to Determine Safety & Efficacy of Bivalirudin vs UFH (BRAVO 2/3)

Effect of Bivalirudin on Aortic Valve Intervention Outcomes 2/3 (BRAVO 2/3)

Sponsor: The Medicines Company

Conditions Aortic Valve Replacement Severe Aortic Stenosis Transcatheter Aortic Valve Replacement

Interventions Bivalirudin Unfractionated Heparin

Updated 8 times since 2017 Last updated: Mar 9, 2017 Started: Oct 31, 2012 Primary completion: Jun 30, 2015 Completion: Jun 30, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Aortic Valve Replacement and Severe Aortic Stenosis, this trial is completed. The trial is conducted by The Medicines Company and has accumulated 8 data snapshots since 2012. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

8 versions recorded

Jan 2026 — Present [monthly]

Completed PHASE3
Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
May 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — May 2017 [monthly]

Completed PHASE3

First recorded

Oct 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

The Medicines Company

Data source: The Medicines Company

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Basel, Switzerland , Bern, Switzerland , Besançon, France , Bonn, Germany , Bremen, Germany , Brighton, United Kingdom , Bron, France , Catania, Italy , Essen, Germany , Freiburg im Breisgau, Germany and 20 more locations